Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

Inclusion Criteria

• •Healthy male or female
• •Between the ages of 18 and 45 years old
• •Able and willing to give informed consent
• •Able to comply with all study procedures
• •If female, must not be of childbearing potential or must agree to use one or more of the following forms of contraception during screening and throughout the study: hormonal (i.e., oral, transdermal, implant or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD); vasectomized partner (6 months minimum); or abstinence
• •Male subjects must also agree to use one or more of the above forms of birth control for either themselves or their partner, as appropriate, throughout the course of the study
• •Not receiving medications within the 2 weeks before the first dose of study medication, except for multivitamins and contraception
• •Complete blood count (CBC) with white blood cell (WBC) count hemoglobin, hematocrit, reticulocyte count and platelet count within normal range for the testing facility or not clinically significant
• •Serum ferritin level \> 50 ng/ml in Cohort 1
• •Serum ferritin level \> 30 mg/ml in Cohorts 2, 3, 4 and 5
• •Serum chemistry values, coagulation tests and urinalysis values within the normal range for the testing facility or not clinically significant
• •Negative urine test for substances of abuse including marijuana, cocaine, opiates, and methadone